JP2024510975A - 前立腺癌を処置する方法 - Google Patents

前立腺癌を処置する方法 Download PDF

Info

Publication number
JP2024510975A
JP2024510975A JP2023555527A JP2023555527A JP2024510975A JP 2024510975 A JP2024510975 A JP 2024510975A JP 2023555527 A JP2023555527 A JP 2023555527A JP 2023555527 A JP2023555527 A JP 2023555527A JP 2024510975 A JP2024510975 A JP 2024510975A
Authority
JP
Japan
Prior art keywords
prostate cancer
compound
cells
acid
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555527A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510975A5 (https=
Inventor
マラテスタ，マルティナ
ホープ フィルバロフ，エレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2024510975A publication Critical patent/JP2024510975A/ja
Publication of JP2024510975A5 publication Critical patent/JP2024510975A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023555527A 2021-03-12 2022-03-10 前立腺癌を処置する方法 Pending JP2024510975A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163160319P 2021-03-12 2021-03-12
US63/160,319 2021-03-12
PCT/US2022/019662 WO2022192481A1 (en) 2021-03-12 2022-03-10 Methods of treating prostate cancer

Publications (2)

Publication Number Publication Date
JP2024510975A true JP2024510975A (ja) 2024-03-12
JP2024510975A5 JP2024510975A5 (https=) 2025-03-18

Family

ID=80952117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555527A Pending JP2024510975A (ja) 2021-03-12 2022-03-10 前立腺癌を処置する方法

Country Status (6)

Country Link
US (1) US12016847B2 (https=)
EP (1) EP4304589A1 (https=)
JP (1) JP2024510975A (https=)
KR (1) KR20230156107A (https=)
CN (1) CN117241797A (https=)
WO (1) WO2022192481A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505762A (ja) * 2013-12-24 2017-02-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗がん剤としての三環式化合物
JP2017511801A (ja) * 2014-02-28 2017-04-27 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン ＢＥＴブロモドメイン阻害剤としての９Ｈ−ピリミド［４，５−ｂ］インドールおよび関連類似体
JP2017537166A (ja) * 2014-12-05 2017-12-14 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 癌免疫療法におけるアジュバントとしてのブロモドメイン阻害剤
WO2017216772A2 (en) * 2016-06-16 2017-12-21 The University Of Chicago Methods and compositions for treating breast and prostate cancer
WO2019080941A1 (en) * 2017-10-27 2019-05-02 Jacobio-Beta Pharmaceuticals Co., Ltd. NEW TRICYCLIC COMPOUNDS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI477503B (zh) 2008-10-31 2015-03-21 Medivation Technologies Inc 含有剛性部分之吡啶并〔４，３－ｂ〕吲哚
CN102257076B (zh) 2008-12-18 2014-07-30 纳幕尔杜邦公司 具有新颜料的粉末涂料组合物
US8580399B2 (en) 2011-04-08 2013-11-12 Universal Display Corporation Substituted oligoazacarbazoles for light emitting diodes
WO2013046635A1 (ja) 2011-09-28 2013-04-04 出光興産株式会社 有機エレクトロルミネッセンス素子用材料及びそれを用いた有機エレクトロルミネッセンス素子
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2961747B1 (en) 2013-02-27 2017-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
EP2970312B1 (en) 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
US9458156B2 (en) * 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505762A (ja) * 2013-12-24 2017-02-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗がん剤としての三環式化合物
JP2017511801A (ja) * 2014-02-28 2017-04-27 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン ＢＥＴブロモドメイン阻害剤としての９Ｈ−ピリミド［４，５−ｂ］インドールおよび関連類似体
JP2017537166A (ja) * 2014-12-05 2017-12-14 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 癌免疫療法におけるアジュバントとしてのブロモドメイン阻害剤
WO2017216772A2 (en) * 2016-06-16 2017-12-21 The University Of Chicago Methods and compositions for treating breast and prostate cancer
WO2019080941A1 (en) * 2017-10-27 2019-05-02 Jacobio-Beta Pharmaceuticals Co., Ltd. NEW TRICYCLIC COMPOUNDS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FAIVRE EMILY J.: "Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel", MOLECULAR CANCER RESEARCH, vol. 15(1), JPN7026000887, 2017, pages 35 - 44, ISSN: 0005807926 *
谷内出友美: "BETブロモドメインを標的としたエピジェネティクス制御", MEDCHEM NEWS, vol. 27(4), JPN7026000886, 2017, pages 213 - 218, ISSN: 0005807925 *

Also Published As

Publication number Publication date
US12016847B2 (en) 2024-06-25
EP4304589A1 (en) 2024-01-17
US20220296574A1 (en) 2022-09-22
KR20230156107A (ko) 2023-11-13
WO2022192481A1 (en) 2022-09-15
CN117241797A (zh) 2023-12-15

Similar Documents

Publication Publication Date Title
US20220265618A1 (en) Methods of treating prostate cancer
EP3704108B1 (en) Irak4 inhibitor in combination with a bcl-2 inhibitor for use in treating cancer
ES2981521T3 (es) Compuestos y procedimientos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales
PT1024814E (pt) Utilização de agentes antifúngicos para o tratamento tópico de mucosite induzida por fungo
ES2376493T3 (es) Procedimiento para reducir o aliviar la inflamación en el tubo digestivo.
JP2024510975A (ja) 前立腺癌を処置する方法
US20120045433A1 (en) Combination therapy
TW201919618A (zh) 用於治療肉瘤的化合物
US8785423B2 (en) Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
US20150141438A1 (en) Methods for delaying or preventing the onset of type 1 diabetes
AU2019354771A1 (en) Combination therapy for the treatment of uveal melanoma
RU2423692C2 (ru) Вещества для профилактики и лечения панкреатита
CN116650490B (zh) 化合物mt-1207在降低尿酸方面的应用
KR102740381B1 (ko) 벤즈이미다졸 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
TW202408469A (zh) 醫藥組合物及其用途
HK40099691A (zh) 用於治疗前列腺癌的溴结构域(bet)抑制剂
US20100204286A1 (en) Method for reducing gastrointestinal adverse effects of cytotoxic agents
JP2019517506A (ja) 血管破壊剤を含む肝臓癌治療用の組成物
CN106580938A (zh) 一种氨丁三醇有机酸盐及其制备方法和应用
US20220062247A1 (en) Use of a par-1 antagonist for the treatment of a chronic inflammatory intestinal disease
CN115364083B (zh) 一种利多卡因衍生物在制备防治肠道屏障损伤产品中的应用
JP2015003902A (ja) 血管新生阻害剤
JP4686704B2 (ja) 動脈瘤予防および／または治療剤
WO2026015820A1 (en) Methods of treating vexas
CN119235867A (zh) 6rk73在制备用于预防或治疗心房颤动药物中的用途

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250307

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303